Gordon Research Conferences

Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on:

Monday, November 13, 2023

SOLANA BEACH, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the three months ended September 30, 2023 and provided a business update.

Key Points:

“We are pleased to report continued progress toward achieving meaningful milestones,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
Notably, ART12.11 demonstrated improved pharmaceutical properties in preclinical chronic stress models due to its novel co-crystallization.
Financial Results Ended September 30, 2023
Operating expenses for the three months ended September 30, 2023, were $2.6 million compared to $2.4 million for the same period in 2022.
As of September 30, 2023, the Company had approximately $12.9 million in cash and investments, compared to $17.5 million as of December 31, 2022.

Evaxion Announces Business Update and Second Quarter 2023 Financial Results

Retrieved on:

Friday, August 18, 2023

COPENHAGEN, Denmark, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today provided a business update and announced its second quarter 2023 financial results.

Key Points:

Cash and cash equivalents of $7.1 million at June 30, 2023 sufficient to fund operations into December 2023
COPENHAGEN, Denmark, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today provided a business update and announced its second quarter 2023 financial results.
Operating spending for the second quarter of 2023 was offset by the proceeds from issue of shares and exercise of warrants.
Research and Development expenses were $2.9 million for the quarter ended June 30, 2023 as compared to $4.1 million for the quarter ended June 30, 2022.
ASCO23 = the 2023 Annual Meeting of the American Society for Clinical Oncology, AACR 2023 = the 2023 Annual Meeting for the American Association for Cancer Research, ERVs = endogenous retroviruses

Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus

Retrieved on:

Monday, July 31, 2023

“I am excited to present the impressive results of EVX-B1 at the Gordon Research Conference.

Key Points:

“I am excited to present the impressive results of EVX-B1 at the Gordon Research Conference.
The demonstration of full disease protection and complete bacterial clearance marks a significant advancement in the fight against this widespread and often antibiotic-resistant pathogen.
With the many previous unsuccessful attempts to develop an effective S. aureus vaccine, EVX-B1 instills renewed hope in the battle against the bacteria,” said Steven Projan, PhD, Scientific Advisor to Evaxion and poster presenter.
The AI technology has enabled the identification of novel S. aureus antigens, paving the way for the development of a vaccine with potential for broad protection against clinically relevant strains.

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023

Retrieved on:

Wednesday, July 19, 2023

Gordon Research Conferences, Diabetic neuropathy, Cancer, National Center for Advancing Translational Sciences, Doctor of Philosophy, Transcriptome, Pain, Gordon, Food and Drug Administration Amendments Act of 2007, FABP, Therapy, IND, Conference, Food, Pharmaceutical industry

https://www.grc.org/cannabinoid-function-in-the-cns-conference/2023/

Key Points:

https://www.grc.org/cannabinoid-function-in-the-cns-conference/2023/
“I am looking forward to sharing our data on the potential applications of inhibiting fatty acid binding proteins from our extensive library of compounds,” said Professor O’Sullivan.
“We are particularly excited to share new information on the effects of our FABP inhibitor ART26.12 on not only cannabinoid receptors, but other receptors implicated in pain signaling, as well as lipidomic and transcriptome data that help us understand how ART26.12 elicits its effects in peripheral neuropathies.”
Professor O’Sullivan’s presentation on Thursday, July 20, 2023 includes data on ART26.12, Artelo’s lead compound targeting a variety of painful neuropathies, as well as the potential of FABP inhibitors beyond peripheral neuropathies.
ART26.12 was selected from Artelo’s platform of inhibitors to FABPs as its first candidate drug.
The Company recently announced it expects pre-IND meeting feedback on its IND planning and development strategy from the Food and Drug Administration during the third quarter of this year with the goal of initiating clinical development in early 2024.

Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference

Retrieved on:

Tuesday, July 18, 2023

Endocannabinoid system, Recycling, Central nervous system, Post-traumatic stress disorder, ECS, Research, Gordon Research Conferences, DSM-IV codes, CNS, CEST, Entrepreneurship, Therapy, Conference, PTSD, Pharmaceutical industry

In particular, Professor Gertsch presented key scientific results that led to the identification and characterization of the biological machinery responsible for endocannabinoid cell reuptake.

Key Points:

In particular, Professor Gertsch presented key scientific results that led to the identification and characterization of the biological machinery responsible for endocannabinoid cell reuptake.
Synendos was founded to exploit the therapeutic potential of this novel mode of action and is developing SERIs as first-in-class inhibitors that modulate a newly identified drug target in the ECS.
The pioneering research performed by Professor Gertsch's team forms the basis of Synendos' approach and represents the most advanced therapeutic approach using this mode of action with clinical studies anticipated in the near future.
Dr Andrea Chicca, Co-Founder and CEO of Synendos, commented: "Professor Jürg Gertsch's groundbreaking findings, disclosed yesterday for the first time, are the culmination of more than a decade of research into an entirely new mechanism for the treatment of challenging neuropsychiatric conditions.

Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference

Retrieved on:

Tuesday, July 18, 2023

In particular, Professor Gertsch presented key scientific results that led to the identification and characterization of the biological machinery responsible for endocannabinoid cell reuptake.

Key Points:

In particular, Professor Gertsch presented key scientific results that led to the identification and characterization of the biological machinery responsible for endocannabinoid cell reuptake.
Synendos was founded to exploit the therapeutic potential of this novel mode of action and is developing SERIs as first-in-class inhibitors that modulate a newly identified drug target in the ECS.
The pioneering research performed by Professor Gertsch's team forms the basis of Synendos' approach and represents the most advanced therapeutic approach using this mode of action with clinical studies anticipated in the near future.
Dr Andrea Chicca, Co-Founder and CEO of Synendos, commented: "Professor Jürg Gertsch's groundbreaking findings, disclosed yesterday for the first time, are the culmination of more than a decade of research into an entirely new mechanism for the treatment of challenging neuropsychiatric conditions.

BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration

Retrieved on:

Friday, July 7, 2023

NEW YORK, July 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, this week presented new biomarker data from the Phase 3 trial of its late-stage investigational ALS treatment, NurOwn at the 2023 ALS and Related Motor Neuron Diseases Gordon Research Conference. These data show that treatment with NurOwn significantly elevated markers of neuroprotection and lowered markers of neuroinflammation and neurodegeneration, including neurofilament light (NfL) over time compared to placebo in all trial participants.

Key Points:

NEW YORK, July 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, this week presented new biomarker data from the Phase 3 trial of its late-stage investigational ALS treatment, NurOwn at the 2023 ALS and Related Motor Neuron Diseases Gordon Research Conference .
These data show that treatment with NurOwn significantly elevated markers of neuroprotection and lowered markers of neuroinflammation and neurodegeneration, including neurofilament light (NfL) over time compared to placebo in all trial participants.
It is believed that reductions in plasma NfL are reasonably likely to predict clinical benefit in ALS.
"The data we presented at the Gordon Research Conference show that it is equally important to examine biomarker data, particularly neurofilament light, which is a predictor of disease progression.

Cerevance Announces Presentation at the Gordon Research Conference: Amyotrophic Lateral Sclerosis and Related Motor Neuron Diseases

Retrieved on:

Monday, June 26, 2023

Central nervous system, Therapy, Cerev Del, ALS, Brain, Gordon Research Conferences, CNS, Mouse, Microglia, Conference, Pharmaceutical industry, Vaccine, KCNK13, VD

BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present a poster presentation at the upcoming Gordon Research Conference: Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases, taking place in Les Diablerets, VD, Switzerland, July 2 – July 7, 2023.

Key Points:

BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present a poster presentation at the upcoming Gordon Research Conference: Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases, taking place in Les Diablerets, VD, Switzerland, July 2 – July 7, 2023.
Overview: Cerevance’s proprietary NETSseq platform can identify novel targets from specific neuronal and glial cell types from the human brain, as illustrated by KCNK13.
Cerevance’s compound, CVN293 is a novel, potent, and selective KCNK13 inhibitor that attenuates the NLRP3-dependent release of IL-1β from microglia and delays disease progression in SOD1(G39A) mice.
The increase in KCNK13 in ALS tissue and the favorable drug metabolism and pharmacokinetics profile of CVN293 support its use in the treatment of ALS.

IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference

Retrieved on:

Tuesday, May 30, 2023

Vaccine, Vaccination, SARS-CoV-2, Drug discovery, COVID-19, Virus, Temperature, Gordon Research Conferences, Messenger, Cell, Therapeutic vaccines, Mouse, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Conference, Food, Fatigue

LAWRENCEVILLE, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., the company’s Executive Vice President and Chief Science Officer, presented new PlaCCine preclinical data at the 2023 Viruses and Cells – Gordon Research Conference in Barcelona. Dr. Khursheed’s presentation, titled “A Novel DNA Vaccine Approach to Prophylactic and Therapeutic Vaccines,” was delivered on May 25, 2023, and described IMUNON’S PlaCCine technology platform for the development of next-generation vaccines. Dr. Anwer’s presentation is available [here].

Key Points:

LAWRENCEVILLE, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., the company’s Executive Vice President and Chief Science Officer, presented new PlaCCine preclinical data at the 2023 Viruses and Cells – Gordon Research Conference in Barcelona.
Dr. Khursheed’s presentation, titled “A Novel DNA Vaccine Approach to Prophylactic and Therapeutic Vaccines,” was delivered on May 25, 2023, and described IMUNON’S PlaCCine technology platform for the development of next-generation vaccines.
In addition, PlaCCine was stable for at least eight months at refrigerated temperatures and for at least one month at room temperature.
Dr. Corinne Le Goff, President and Chief Executive Officer of IMUNON, said, “These preclinical findings underscore the potential of our PlaCCine platform to produce next-generation COVID-19 vaccines that address the limitations of the current commercial products.

Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on:

Wednesday, May 3, 2023

ET today

Key Points:

ET today
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.
“We are well-capitalized through our existing cash and potential near-term milestones to deliver on a steady cadence of clinical data across 2023 and 2024.
At multiple scientific conferences in the first quarter of 2023, Wave highlighted the preclinical data supporting WVE-006, its GalNAc-conjugated candidate for AATD.
ET to review first quarter 2023 financial results and pipeline updates.